Author: Oncotarget

TP53 Mutated AML: Transplant or No Transplant

October 11, 2024

“In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.” BUFFALO, NY- October 11, 2024 – A new editorial was published… read more

Oncotarget

Zika Virus as a Treatment for Brain Cancer: A Systematic Review

October 9, 2024

“Despite limited human evidence, it shows potential benefits.” BUFFALO, NY- October 9, 2024 – A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Zika virus… read more

Oncotarget

Lessons from ACDC-RP Trial: Designing Neoadjuvant Therapy Trials for Prostatectomy

October 7, 2024

“While the ACDC-RP trial adds to the litany of negative trials in this disease space, there are key takeaways from this trial that can inform future clinical trial design.” BUFFALO,… read more

Oncotarget

Exploring UBA1 Dysfunction in VEXAS Syndrome and Cancer

October 3, 2024

“Ultimately, a thorough grasp of the pathogenesis of VEXAS, from genetic mutations to clinical manifestations, will be pivotal in devising safe and effective therapeutic strategies to fight this challenging disease.”… read more

Oncotarget

FOXM1 and PD-L1 in CDK4/6-MEK Resistance in Nerve Tumors

October 1, 2024

“We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients.” BUFFALO, NY- October 1, 2024 –… read more

Oncotarget

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy

September 19, 2024

“We explore how integrating these technologies could revolutionize personalized oncology.” BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled,… read more

Oncotarget

ISR Activation & Apoptosis via HRI Kinase by PG3 and Other p53 Cancer Therapies

September 18, 2024

“Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression.” BUFFALO, NY- September 18, 2024 – A new… read more

Oncotarget

Targeting CD47/SIRPα “Do Not Eat Me” Axis: Advances and Challenges in Cancer Therapy

September 11, 2024

“Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets.” BUFFALO, NY- September 11, 2024… read more

Oncotarget

Next-Gen Vaccines Offer New Hope Against Glioblastoma

September 9, 2024

“Vaccines have been considered a promising approach for GBM for many years.” BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5,… read more

Oncotarget

Generative AI in Cancer Imaging: Revolutionizing Detection & Diagnosis

September 6, 2024

“This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.” BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15… read more